CN102574859A - 作为体内显像剂的[18f]-标记氟马西尼类似物 - Google Patents

作为体内显像剂的[18f]-标记氟马西尼类似物 Download PDF

Info

Publication number
CN102574859A
CN102574859A CN2010800457017A CN201080045701A CN102574859A CN 102574859 A CN102574859 A CN 102574859A CN 2010800457017 A CN2010800457017 A CN 2010800457017A CN 201080045701 A CN201080045701 A CN 201080045701A CN 102574859 A CN102574859 A CN 102574859A
Authority
CN
China
Prior art keywords
compound
radiofluorination
limits
gaba
qualification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800457017A
Other languages
English (en)
Chinese (zh)
Inventor
J·伍德克拉夫特
C·琼斯
A·盖塔
W·特里格
P·琼斯
S·普兰特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of CN102574859A publication Critical patent/CN102574859A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K51/047—Benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2010800457017A 2009-10-08 2010-10-08 作为体内显像剂的[18f]-标记氟马西尼类似物 Pending CN102574859A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0917612.4 2009-10-08
GBGB0917612.4A GB0917612D0 (en) 2009-10-08 2009-10-08 In vivo imaging agents
US25089009P 2009-10-13 2009-10-13
US61/250890 2009-10-13
PCT/EP2010/065126 WO2011042550A1 (en) 2009-10-08 2010-10-08 [18 f] - labelled analogues of flumazenil as in vivo imaging agents

Publications (1)

Publication Number Publication Date
CN102574859A true CN102574859A (zh) 2012-07-11

Family

ID=41402711

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800457017A Pending CN102574859A (zh) 2009-10-08 2010-10-08 作为体内显像剂的[18f]-标记氟马西尼类似物

Country Status (6)

Country Link
US (1) US20120189547A1 (enExample)
EP (1) EP2486043A1 (enExample)
JP (1) JP2013507345A (enExample)
CN (1) CN102574859A (enExample)
GB (1) GB0917612D0 (enExample)
WO (1) WO2011042550A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101441406B1 (ko) * 2011-05-25 2014-11-04 주식회사 바이오이미징코리아 디아릴이오도늄 염 전구체를 이용한 플로오린-18이 표지된 플루마제닐의 제조 방법
GB201117786D0 (en) * 2011-10-14 2011-11-30 Ge Healthcare Ltd Eluent vial
GB201117785D0 (en) * 2011-10-14 2011-11-30 Ge Healthcare Ltd Improved radiosynthesis method
WO2014047413A1 (en) * 2012-09-21 2014-03-27 Uwm Research Foundation, Inc. Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
WO2023213757A1 (en) * 2022-05-03 2023-11-09 F. Hoffmann-La Roche Ag Pet tracers for visualizing gabaa gamma1 receptors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316839A (en) * 1979-10-04 1982-02-23 Hoffman-La Roche Inc. Imidazodiazepine derivatives
US4670433A (en) * 1985-03-08 1987-06-02 A/S Ferrosan Oxadiazolyl imidazobenzodiazepine derivatives pharmaceutical compositions thereof, and method of treating therewith

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0524851D0 (en) * 2005-12-06 2006-01-11 Ge Healthcare Ltd Radiolabelling method using polymers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316839A (en) * 1979-10-04 1982-02-23 Hoffman-La Roche Inc. Imidazodiazepine derivatives
US4670433A (en) * 1985-03-08 1987-06-02 A/S Ferrosan Oxadiazolyl imidazobenzodiazepine derivatives pharmaceutical compositions thereof, and method of treating therewith

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARKUS MITTERHAUSER ET AL.: "Biological evaluation of 2’-18F fluoroflumazenil 18F FFMZ, a potential GABA receptor ligand for PET", 《NUCLEAR MEDICINE AND BIOLOGY》, vol. 31, 31 December 2004 (2004-12-31) *
NIKOLAJ N. RYZHIKOV ET AL.: "Preparation of highly specific radioactivity 18F flumazenil and its evaluation in cynomolgus monkey by positron emission tomography", 《NUCLEAR MEDICINE AND BIOLOGY》, vol. 32, 31 December 2005 (2005-12-31) *

Also Published As

Publication number Publication date
EP2486043A1 (en) 2012-08-15
US20120189547A1 (en) 2012-07-26
WO2011042550A1 (en) 2011-04-14
GB0917612D0 (en) 2009-11-25
JP2013507345A (ja) 2013-03-04

Similar Documents

Publication Publication Date Title
JP6370361B2 (ja) アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物
JP5730206B2 (ja) 神経炎症のイメージング
CN102574859A (zh) 作为体内显像剂的[18f]-标记氟马西尼类似物
CN102355899B (zh) 用于体内成像的放射性标记的吡啶基衍生物
JP5870031B2 (ja) 自動化放射合成
US9186424B2 (en) Aryloxyanilide imaging agents
WO2012131037A1 (en) Radiolabelled flumazenil derivatives
HK1172332A (en) Automated radiosynthesis
WO2011124713A1 (en) Labelled huprine derivatives and their use in medical imaging

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120711